A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain

Pain

Volumn 103, Issue 1-2, 2003, Pages 175-186

  Kehl, Lois J ^a   Hamamoto, Darryl T ^a   Wacnik, Paul W ^b   Croft, Devin L ^a   Norsted, Blake D ^a   Wilcox, George L ^b   Simone, Donald A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bone cancer; Cannabinoid receptors; Carrageenan inflammation; Grip force; Hyperalgesia; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANALGESIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARRAGEENAN; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CANCER PAIN; CATALEPSY; CELL CLONE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FORELIMB; HUMERUS; HYPERALGESIA; INFLAMMATION; MALE; MOTOR DYSFUNCTION; MOUSE; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PRIORITY JOURNAL; TRICEPS BRACHII MUSCLE;

EID: 0038582327     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00450-5     Document Type: Article

References (96)

1. Banning A., Sjogren P., Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain. 47:1991;129-134.
2. Brescia F.J., Portenoy R.K., Ryan M., Krasnoff L., Gray G. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol. 10:1992;149-155.
3. Bruera E., Schoeller T., Wenk R., MacEachern T., Marcelino S., Hanson J., Suarez-Almazor M. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 10:1995;348-355.
4. Cain D.M., Wacnik P.W., Turner M., Wendelschafer-Crabb G., Wilcox G.W., Kennedy W.R., Simone D.A. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci. 21:(23):2001;9367-9376.
5. Calignano A., LaRana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 396:1998;277-281.
6. Carver A.C., Foley K.M. Complications of cancer and its treatment. Bast R.C., Kufe D.W., Pollock R.E., Weichselbaum R.R., Holand J.F., Frei E. Cancer medicine. 5th ed. 2000;2204-2223 B.C. Decker Inc, Hamilton. American Cancer Society.
7. Chang H.M. Cancer pain management. Med Clin North Am. 83:1999;711-736.
8. Cherny N.I. The management of cancer pain. CA Cancer J Clin. 50:2000;70-119.
9. Chirgwin J.M., Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 10:2000;159-178.
10. 9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 289:1999;859-867.
11. Cleeland C.S., Gonin R., Hatfield A.K., Edmonson J.H., Blum R.H., Stewart J.A., Pandya K.J. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 330:1994;592-596.
12. Clohisy D.R., Ogilvie C.M., Carpenter R.J., Ramnaraine M.L. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res. 14:1996;2-6.
13. Costa-Campos L., Lara D.R., Nunes D.S., Elisabetsky E. Antipsychotic-like profile of alstonine. Pharmacol Biochem Behav. 60:1998;133-141.
14. Costall B., Naylor J., Olley J.E. Catalepsy and circling behavior after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology. 11:1972;645-663.
15. Croft D.L., Norsted B.D., Wacnik P.W., Kehl L.J., Wilcox G.L., Simone D.A., Hamamoto D.T. The cannabinoid receptor agonist WIN55,212-2 attenuates muscle hyperalgesia associated with osteolytic tumor growth. J Dent Res. 80:2001;141.
16. DePetrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., DiMarzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 95:1998;8375-8380.
17. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
18. Dunajcik L. Chronic nonmalignant pain. McCaffery M., Pasero C. Pain clinical manual. 1999;467-521 Mosby, St. Louis, MO.
19. Edsall S.A., Knapp R.J., Vanderah T.W., Roeske W.R., Consroe P., Yamamura H.I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport. 7:1996;593-596.
20. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA. 92:1995;3376-3380.
21. Fonsatti E., Altomonte M., Coral S., Cattarossi I., Nicotra M.R., Gasparollo A., Natali P.G., Maio M. Tumour-derived interleukin 1 alpha (IL-1 alpha) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. Br J Cancer. 76:1997;1255-1261.
22. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
23. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 279:1991;129-134.
24. Glezerman M., Mazot M., Maymon E., Piura B., Prinsloo I., Benharroch D., Yanai-Inbar I., Huleihel M. Tumor necrosis factor-alpha and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines. Eur Cytokine Netw. 9:1998;171-179.
25. 9-THC in the rat. Neuropharmacology. 17:1978;137-144.
26. Hanus L., Abu-Lafi S., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA. 98:2001;3662-3665.
27. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 96:1999;14228-14233.
28. Helig S. The San Francisco medical society euthanasia survey: results and analysis. SF Med. 61:1988;24-34.
29. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160.
30. Hida T., Leyton J., Makheja A.N., Ben-Av P., Hla T., Martinez A., Mulshine J., Malkani S., Chung P., Moody T.W. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 18:1998;775-782.
31. Hitchcock L.S., Ferrell B.R., McCaffery M. The experience of 'chronic nonmalignant pain'. J Pain Symptom Manage. 9:1994;312-318.
32. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci Lett. 257:1998;119-122.
33. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Acta Pharmacol Sin. 20:1999;1132-1136.
34. Hollister L.E. Marijuana and immunity. J Psychoactive Drugs. 20:1988;3-8.
35. Holzberg A.D., Robinson M.E., Geisser M.E., Gremillion H.A. The effects of depression and chronic pain on psychosocial and physical functioning. Clin J Pain. 12:1996;118-125.
36. Honore P., Schwei M.J., Roger S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog Brain Res. 129:2000;389-397.
37. Jagger S.I., Hasnie F.S., Sellaturay S., Rice A.S.C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
38. Janjan N.A., Payne R., Gillis T., Pololoff D., Libshitz H.I., Lenzi R., Theriault R., Martin C., Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage. 16:1998;171-178.
39. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain. 93:2001;303-315.
40. Kantor T.G. The pharmacological control of musculoskeletal pain. Can J Physiol Pharmacol. 69:1990;713-718.
41. Kehl L.J., Trempe T.M., Hargreaves K.M. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain. 85:2000;333-343.
42. Klein T.W., Kawakami Y., Newton C., Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health. 32:1991;465-477.
43. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology. 143:1999;322-326.
44. Li J., Daughters R.S., Bullis C., Bengiamin R., Stucky M.W., Brennan J., Simone D.A. The cannabinoid receptor agonist WIN55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain. 81:1999;25-33.
45. Lichtman A.H., Martin B.R. Cannabinoid induced antinociception is mediated by a spinal α2 noradrenergic mechanism. Brain Res. 559:1991;309-314.
46. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 276:1996;585-593.
47. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 247:1988;1046-1051.
48. 2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
49. Mao J., Price D.D., Lu J., Keniston L., Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett. 280:2000;13-16.
50. 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend. 37:1995;231-240.
51. Martin W.J., Coffin P.O., Attias E., Balinsky M., Tsou K., Walker J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 822:1999;237-242.
52. Martin W.J., Loo C.J., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rat with persistent inflammation. Pain. 82:1999;199-205.
53. Martin W.J., Tsou K., Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett. 242:1998;33-36.
54. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:(6284):1990;561-564.
55. McCain G.A. Fibromyalgia and myofascial pain. Wall P.D., Melzack R. Textbook of pain. 1994;475-493 Churchill Livingstone, New York, NY.
56. 9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther. 273:1995;1216-1223.
57. McCoy K.L., Matveyeva M., Carlisle S.J., Cabral G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther. 289:1999;1620-1625.
58. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., Gopher A., Almog S., Martin B., Compton D., Pertwee R., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
59. Medhurst S.J., Walker K., Bowes M., Kidd B.L., Glatt M., Muller M., Hattenberger M., Vaxelaire J., O'Reilly T., Wotherspoon G., Winter J., Green J., Urban L. A rat model of bone cancer pain. Pain. 96:2002;129-140.
60. Mense S., Simons D.G. Muscle pain: understanding its nature, diagnosis, and treatment. 2001;Lippincott Williams & Wilkins, Baltimore, MD. p. 7-15.
61. Mercadante S., Maddaloni S., Roccella S., Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 50:1992;151-155.
62. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
63. Nasu K., Matsui N., Narahara H., Tanaka Y., Takai N., Miyakawa I., Higuchi Y. MaMi: a human endometrial stromal sarcoma cell line that constitutively produces interleukin-6, interleukin-8, and monocyte chemoattractant protein-1. Arch Pathol Lab Med. 122:1998;836-841.
64. Nguyen T.N., Wacnik P.W., Harding-Rose C.A., Wilcox G.L., Simone D.A., Hamamoto D.T. Co-administration of morphine and a cannabinoid receptor agonist, WIN55,212-2. J Dent Res. 81:2002;A454.
65. Norsted B.D., Croft D.L., Wacnik P.W., Hamamoto D.T., Wilcox G.L., Simone D.A., Kehl L.J. The cannabinoid receptor agonist WIN55,212-2 attenuates carrageenan-evoked muscle hyperalgesia. J Dent Res. 80:2001;142.
66. Noyes R., Brunk F., Avery D.H., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 18:1975;84-89.
67. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol. 63:2001;569-611.
68. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 6:1999;635-664.
69. Petro P.J. Marijuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics. 21:1980;81-85.
70. Portenoy R.K., Payne D., Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 81:1999;129-134.
71. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 301:2002;1020-1024.
72. 9-THC, WIN55,212-2 and anandamide in mice. Neurosci Lett. 263:1999;29-32.
73. Richardson J.D., Aanonsen L., Hargreaves K.M. Anti-hyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 345:1998;145-153.
74. Richardson J.D., Kilo S.K., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119.
75. Sanudo-Pena M.C., Romero J., Seale G.E., Fernandez-Ruiz J., Walker J.M. Activational role of cannabinoids on movement. Eur J Pharmacol. 391:2000;269-274.
76. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 19:1999;10886-10897.
77. Shimoyama M., Tanaka K., Hasue F., Shimoyama N. A mouse model of neuropathic cancer pain. Pain. 99:2002;167-174.
78. 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 60:1998;183-191.
79. 9-tetrahydrocannabinol-induced antinociception in mice without altering other pharmacological effects. J Pharmacol Exp Ther. 268:1993;1381-1387.
80. Staquet M., Gantt C., Machin B. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther. 23:1978;397-401.
81. Strang P. Cancer pain: a provoker of emotional, social and existential distress. Acta Oncol. 37:1998;641-644.
82. Strangman N.M., Walker J.M. Cannabinoid WIN55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol. 82:1999;472-477.
83. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 215:1995;89-97.
84. Tallarida R., Murray R. Manual of pharmacological calculations with computer programs. 1987;Springer, New York, NY.
85. Ushijima I., Kawano M., Kaneyuki H., Suetsugi M., Usami K., Hirano H., Mizuki Y., Yamada M. Dopaminergic and cholinergic interaction in cataleptic responses in mice. Pharmacol Biochem Behav. 58:1997;103-108.
86. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., Wilcox G.L. Functional interactions between tumor and peripheral nerve: morphology, algogen identification and behavioral characterization of a new murine model of cancer pain. J Neurosci. 21:2001;9355-9366.
87. Wacnik P.W., Kehl L.J., Trempe T.M., Ramnaraine M.L., Beitz A.J., Wilcox G.L. Sarcoma tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain. 101:2003;175-186.
88. Wacnik P.W., Wilcox G.L., Clohisy D.R., Ramnaraine M.R., Eikmeier L.J., Beitz A.J. Cancer pain mechanisms and animal models of cancer pain. Devor M., Rowbotham M.C., Wiesenfeld-Hallin Z. Proceedings of the 9th world congress on pain. 2000;615-637 IASP Press, Seattle, WA.
89. Ward S.J. Commentary on 'cannabinoids modulate pain by multiple mechanisms of action'. J Pain. 1:2000;15-17.
90. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther. 262:1992;10-18.
91. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther. 286:1998;1301-1308.
92. Welch S.P., Dunlow L.D., Patrick G.S., Razdan R.K. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J Pharmacol Exp Ther. 273:1995;1235-1244.
93. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther. 272:1995;310-321.
94. Cancer pain relief with a guide to opioid availability. 2nd ed. Technical report series. 1996;World Health Organization, Geneva.
95. 9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 165:2000;373-380.
96. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.